Twenty-one consecutive patients with streptococcal toxic shock syndrome (TSS) between December 1994 and April 1995 were treated with a median dose of 2 g of intravenous immunoglobulin (IVIG)/kg (cases) and were compared with 32 patients with streptococcal TSS between 1992 and 1995 who did not receive IVIG therapy (controls). The outcome measure was 30-day survival. Patient plasma was tested for its ability to inhibit T cell activation induced by the infecting strain. The proportion of cases with 30-day survival was higher than that of the controls with 30-day survival (67% vs. 34%, respectively; P Å .02). Multivariate analysis revealed that IVIG administration and a lower Acute Physiology and Chronic Health Evaluation II score were associated with survival; the odds ratio for survival associated with IVIG therapy was 8.1 (95% confidence interval, 1.6 -45; P Å .009). IVIG therapy enhanced the ability of patient plasma to neutralize bacterial mitogenicity and reduced T cell production of interleukin-6 and tumor necrosis factor a. IVIG may be an effective adjunctive therapy for streptococcal TSS, possibly because of its ability to neutralize bacterial exotoxins.
Streptococcal toxic shock syndrome (TSS) is the most severe tion and cytokine production [7] . Administration of intravenous immunoglobulin (IVIG) can block in vitro T cell activation by manifestation of invasive disease due to group A streptococcus (GAS); the case-fatality rate associated with streptococcal TSS staphylococcal and streptococcal superantigens [8 -10] . Several case reports have been published in which IVIG adminisis as high as 81% [1 -6] . The mechanism whereby gram-positive organisms cause shock is as yet not determined, but there tration in the setting of streptococcal TSS appeared to correlate with clinical improvement [11 -15] , and there is evidence that is increasing evidence that it is the result of cytokine induction by exotoxins(s) belonging to the family of gram-positive bacte-IVIG contains superantigen-neutralizing antibodies [16] . The Ontario Streptococcal Study Group has conducted popurial superantigens. This family includes the enterotoxins and TSS toxin-1 produced by Staphylococcus aureus and the streplation-based surveillance for all invasive GAS disease in Ontario, Canada, since 1 January 1992 [6] . The case-fatality rate tococcal pyrogenic exotoxins of Streptococcus pyogenes [7, 8] .
Superantigens bind to cells expressing major histocompatiassociated with streptococcal TSS has been ú65% and has remained stable over time [6, 17] . In the winter of 1994, noting bility complex class II molecules and interact directly with the b chain of the T cell receptor to cause massive T cell proliferaan increase in rates of streptococcal TSS [17] and recognizing the potential for IVIG to decrease the high case-fatality rates associated with this disease, we initiated an observational study of the use of IVIG to treat patients with GAS TSS.
with GAS TSS. The treatment protocol recommended IVIG, Categorical variables were analyzed by Fisher's exact test, and continuous variables were analyzed by the Student's t test clindamycin, and penicillin and early surgical debridement if appropriate. Physicians enrolling patients requested consent for or Wilcoxon rank-sum or signed-rank test [19] . For stratified analyses of categorical variables, summary odds ratios were the collection of detailed clinical data, the GAS isolate, and blood samples before and immediately after IVIG infusions. calculated, and significance was analyzed by the CochranMantel-Haenzel x 2 test. Multivariate analysis was carried out The IVIG used in this study was provided by the Canadian Red Cross and Cutter Biologicals (Toronto). Initial dosage recby two methods: generalized additive modeling in the S language [20] was performed, to remove possible nonlinear efommendations were 0.4 g/kg daily for 5 days; in March 1995, the recommendation was changed to a single dose of 2 g/kg, fects of continuous covariates, and propensity score analysis was performed [21 -23] , to assess group comparability before with a repeated dose at 48 hours if the patient remained unstable. IgA deficiency was the only absolute contraindication to and after stratification by APACHE II score that was based on the estimated probability of receiving IVIG. The variables IVIG therapy, although patient hypervolemia might limit the rate of administration.
included in both multivariate models were those associated with survival in the univariate analysis (P õ .1) and potential Because the magnitude of any therapeutic effect of IVIG was unknown and because severe GAS infections are seasonal confounding variables. P values of £.05 were considered statistically significant. (in Ontario, ú70% of cases occur during the winter and spring months [6, 17] ), an a priori decision was made to include in the treatment group patients enrolled during a single season, Laboratory Methods from 1 December 1994 to 30 April 1995. The study was approved by the Human Subjects Review Committee of the UniClinical isolates were identified as GAS by conventional versity of Toronto.
methods [24] . M typing and T typing, according to capillary precipitin and agglutination reactions, respectively, were per-
Study Enrollment
formed with use of specific antisera at the National Reference Centre for the Streptococcus, Edmonton, Alberta, Canada [25, The efficacy of IVIG was assessed by comparing outcomes 26]. Specific PCR primers were used to detect the genes enfor IVIG-treated patients (cases) with those for patients receivcoding streptococcal pyrogenic exotoxins A (speA) and C ing standard care (controls). Cases were patients with strepto-(speC) [27] . coccal TSS who received IVIG therapy within the study period;
Additional immunologic analyses were performed on plasma these patients were enrolled from across Canada. All cases samples from all 10 cases from whom both baseline and postwere enrolled into the study before the administration of IVIG.
IVIG infusion specimens were available and on baseline Any patient with streptococcal TSS who was identified by plasma samples from the 10 controls most closely matching active surveillance in southern Ontario between 1 January 1992 these cases according to age and APACHE II score. The ability and 30 April 1995 was screened for possible inclusion in the of each patient's plasma to inhibit the mitogenicity of the culcontrol group. Controls were excluded from analysis if they ture supernatant from their own GAS isolate was assessed as had not received antibiotic therapy appropriate for GAS sepsis, previously described [10, 28] . Plasma samples resulting in if they died õ12 hours after meeting the criteria for streptococ- §50% inhibition of mitogenic activity were considered to poscal TSS, if the severity of preexisting illness precluded aggressess mitogen-neutralizing capacity [28] . sive supportive care, if they had received IVIG therapy outside
The impact of a single IVIG infusion on the production of of the study period, if their charts were not available for review, IL-6 and TNF-a by peripheral blood mononuclear cells or if they had known IgA deficiency.
(PBMCs) was assessed at the single cell level by staining with The Acute Physiology and Chronic Health Evaluation II monoclonal antibodies according to previously described meth-(APACHE II) score [18] was calculated for each patient on ods [10, 16, 29] . Data are presented as the mean percent of the basis of age, underlying illness, and vital signs and laboracytokine-producing cells { SD; these mean values were calcutory results obtained at the time that the patient first met criteria lated from duplicate runs, counting 1,000 cells per slide. for streptococcal TSS. For univariate analysis, cases and controls were stratified into four groups according to APACHE II score (1 -19 points, 20 -29 points, 30 -39 points, and §40 Results points). The primary outcome was 30-day survival. Secondary
Clinical and Microbiological Characteristics
end points were 7-day survival and the duration of survivors' mechanical ventilation and hospitalization.
Twenty-one cases were enrolled in the study. Twelve cases (57%) were identified through active surveillance in Ontario,
Statistical Analysis
and nine (43%) were identified through surveillance in other provinces of Canada, one of whom has been previously deUnivariate analysis was performed with use of Epi-Info Version 6.02 (Centers for Disease Control and Prevention).
scribed [13] . Three patients were enrolled in December 1994, / 9c64$$ap19 03-15-99 09:57:41 cida UC: CID year to year (data not shown). There was also no difference in the case-fatality rate among cases from Ontario who were southern Ontario (66%) was not significantly different from that among patients from northern and eastern Ontario (83%; treated between 1992 and 1995 in teaching and nonteaching hospitals (64% vs. 69%, respectively; P Å .56). P Å .24). Twenty-six of the patients with streptococcal TSS who were from southern Ontario were ineligible for the study Cases and controls were similar in regard to demographics, APACHE II score, and timing of interventions, although cases (case-fatality rate, 92%): 2 had received IVIG therapy outside of the study period (both survived), 6 had not received aggreshad more dysfunction of major organ systems, as defined by the Working Group on Severe Streptococcal Infections [5] , sive supportive care (all died), and 18 died õ12 hours after meeting criteria for streptococcal TSS. None of the patients than did controls (mean: 3.0 vs. 2.5 major organ systems, respectively; P Å .05) (table 1). Cases were also more likely to had contraindications to IVIG therapy. Consent for additional chart review could not be obtained for four patients (two died), have received clindamycin therapy and to be infected with organisms of M1 serotype (table 1) . and medical records could not be traced for one patient who died. The remaining 32 patients were enrolled in the study as Initial doses of IVIG were 0.2 g/kg (2 cases), 0.4 g/kg (11), 0.5 g/kg (2), 1 g/kg (3), and 2 g/kg (3). The median cumulative controls.
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Neutralization of Streptococcal Mitogenic Activity
Baseline and post -IVIG infusion plasma samples from 10 dose of IVIG was 2 g/kg (range, 0.2 -3.6 g/kg). Neither the size of the initial dose nor the cumulative dose of IVIG adminiscases were analyzed, as were baseline plasma samples from 10 controls matched for mean age (52 vs. 47 years, respectively; tered was associated with outcome (data not shown). Treating physicians reported no significant adverse reactions to IVIG. P Å .6) and mean APACHE II score (24.6 vs. 25.6, respectively; P Å .8). The inhibitory capacity of baseline plasma varied from 0 to 97%, and there was no significant difference
Univariate Analysis
between cases and controls (P Å .20; figure 1 ). There was a significant increase in mitogen-neutralizing capacity after a sinThe overall case-fatality rate associated with streptococcal TSS was 56% and increased as the APACHE II score increased gle dose of IVIG (P Å .004, Wilcoxon signed-rank test), with eight of 10 cases exhibiting mitogen-neutralizing activity after (1 -19 points, 31%; 20 -29 points, 43%; 30 -39 points, 77%; §40 points, 100%; P Å .02, x 2 test for trend). Cases were one dose (figure 1). Plasma from one of the two remaining cases exhibited neutralizing activity after a second IVIG dose. more likely than controls to survive for both 7 and 30 days in the stratified analysis (P Å .007 and .02, respectively; tables IVIG therapy resulted in a statistically significant decrease in IL-6 production by PBMCs for all four patients treated (for 2 and 3). The duration of hospitalization and intubation for survivors did not differ significantly between the two groups each patient, P õ .05 by the t test) and in TNF-a production by PBMCs for three of the four patients treated (figure 2). (table 2) .
Logistic and Propensity Score Analyses

Discussion
The advent of antibiotics dramatically reduced the mortality Variables included in the multivariate model included APACHE II score (which incorporates the presence of underlyrate associated with invasive bacterial infections [30] . However, despite antibiotic therapy and intensive care unit support, ing illness and age), IVIG therapy, clindamycin and penicillin therapy, surgery, presence of necrotizing fasciitis, speA and rates of early death due to serious streptococcal infections remain high [6, 30, 31] , suggesting that new therapeutic apspeC genotypes, and M1 and M3 serotypes. APACHE II score and IVIG therapy were the two variables retained in this modelproaches are needed. Recently, a number of case reports have suggested that IVIG may fulfill this role [11 -15] . These case ing. The odds ratio for survival of cases as compared with controls was 8.1 (95% CI, 6 -45; P Å .009). The information reports are supported by the fact that there is a biologically plausible mechanism for this effect and by the fact that IVIG for patients not treated with clindamycin is limited by the fact that 20 (95%) of 21 cases received clindamycin compared with may have an impact on mortality due to sepsis caused by other gram-positive organisms [32] . 17 (55%) of 31 controls. This circumstance occurred because the treatment protocol recommended by the study included Double-blind, randomized, controlled trials are the standard method for evaluating new therapies. The advantages of this clindamycin as well as IVIG therapy. In a secondary multivariate analysis, considering only those cases and controls treated approach are that investigators, blinded to assignment of ther-/ 9c64$$ap19 03-15-99 09:57:41 cida UC: CID apy, cannot introduce bias in classifying outcomes and that from Ontario. This difference could affect study outcome if cases were enrolled from facilities where more aggressive treatprospective, randomized assignment to treatment group should lead to an equal distribution of potential confounders between ment and supportive care were provided and a larger number of controls were enrolled from facilities providing varying therapies. A randomized, controlled trial, however, may be logistically extremely difficult when a rare condition requiring quality of care. However, we found no difference in outcome between cases enrolled from active surveillance and those enimmediate therapy is being studied. In the face of increasing population-based rates of streptococcal TSS in 1994, we derolled from elsewhere in Canada or between cases from teaching and nonteaching hospitals in Ontario. Bias might also have signed a comparative observational study, combined with an in vitro assessment of effect, to further our understanding of been introduced in our exclusion of some patients with streptococcal TSS as controls or because cases and controls were the value of IVIG therapy.
The major concern in assessing results from observational enrolled during different times. These practices would bias results toward finding an effect of IVIG if excluded persons studies is the comparability of the treatment and control groups. Patients are not randomly assigned to treatment group; therewere less likely to die or if patients enrolled in 1995 were less likely to die than those affected in previous years. We found, fore, potential sources of bias must be recognized and minimized, and potential confounders must be controlled for in the however, that the case-fatality rate was significantly higher among excluded controls than among included controls (87% analysis. In this study, we did this by analyzing the results with both a multivariate analysis model and a propensity score vs. 68%, respectively; P Å .05) and that there was no change in the case-fatality rate associated with streptococcal TSS among model [22, 23] . Multivariate modeling expresses the risk of the outcome as a function of the exposure of interest and the controls between 1992 and 1995. We took other potential sources of bias into account in the confounders. Propensity score analysis stratifies on the basis of a propensity score, which is obtained from a logistic regression analysis. We controlled for potential differences in age and severity of illness between groups by including APACHE model that assesses the probability of the exposure itself as a function of the confounders. Although the finding of an IVIG II scores in both univariate and multivariate analyses. The APACHE II scoring system is a validated severity of illness effect in both types of models is reassuring, the success of both models depends on the appropriate identification and control scale that accurately predicts in-hospital mortality rates among critically ill patients [18, 33] . The only two statistiof the effects of bias and confounding.
Thus, the results of this study must be considered in the cally significant differences between demographic and clinical characteristics of groups at baseline, major organ dyscontext of several potential sources of bias. The choice of death as the primary outcome avoids issues of bias in classifying function at study enrollment (P Å .05) and M1 serotype (P õ .01), tended to bias toward a more favorable outcome outcomes; however, bias may have been introduced because cases were from throughout Canada and controls were only for the controls [34, 35] . It is important to remember, how-/ 9c64$$ap19 03-15-99 09:57:41 cida UC: CID cell stimulation and subsequent cytokine release induced by one or more superantigens [41] . It has been shown that different IVIG preparations vary in their ability to inhibit GAS supernatant -induced mitogenicity and that they vary in their ability to induce this activity in postadministration patient plasma [42] . However, the clinical relevance of this observation is not clear at present. This study adds to data from case reports suggesting that IVIG is associated with improved outcomes for persons with Figure 1 . Inhibition of mitogenicity of bacterial culture supernatants by plasma from patients with streptococcal toxic shock syndrome who were treated with (cases, l) and without (controls, ᭝) intravenous immunoglobulin (IVIG). Supernatants from infecting strains of group A streptococci were used to stimulate peripheral blood mononuclear cells from a healthy individual. Cells were cultured in 10% fetal calf serum in the presence or absence of 1% patient plasma and stimulated with 1% supernatant produced by the infecting group A streptococcus isolate. Post -IVIG 1 Å plasma sample obtained within 24 hours of the completion of the first IVIG infusion; post -IVIG 2 Å plasma sample obtained within 24 hours after the second IVIG infusion. There was no difference in the mitogen-neutralizing capacity at baseline for cases and controls (P Å .20, Wilcoxon rank-sum test); however, post -IVIG plasma had significantly greater neutralizing capacity than did pre -IVIG plasma (P Å .004, Wilcoxon signed-rank test).
ever, that there remains considerable controversy about the importance of various GAS virulence factors and that the small sample size limited our ability to identify and adjust for all the potential confounders.
Because cases were enrolled prospectively and recommendations were made regarding the need for clindamycin therapy and aggressive surgery, cases were more likely to have been treated with both clindamycin and surgery than were controls. Studies with animals have suggested that clindamycin is more active against GAS than several antibiotics, including penicillin, and that it may reduce exotoxin production by inhibiting bacterial protein synthesis [36, 37] . Because all cases but one were also treated with clindamycin, we cannot assess the efficacy of IVIG in the absence of clindamycin or rule out the possibility that clindamycin is a necessary cofactor for the efficacy of IVIG in streptococcal TSS. However, in the subgroup analysis including only patients treated with clinda- There is considerable evidence that mitogenic streptococcal after (ᮀ) intravenous immunoglobulin treatment were fixed on glass slides and stained with monoclonal antibodies specific to IL-6 (A) exotoxins contribute to the pathogenesis of streptococcal TSS and TNF-a (B). Cells displaying dense juxtanuclear staining after and that this contribution may be through their ability to funcapplication of an avidin-biotin label were visually quantified as the tion as superantigens [10, 16, 34, 35, 38 -40] . In this study, mean percentage of cytokine-producing cells { SD. IL-6 production the ability of patient plasma to inhibit the mitogenicity of the was significantly (for each patient, P õ .05 by the t test) reduced in bacterial supernatant was significantly increased after IVIG all four patients; TNF-a production was significantly reduced in patients 2, 3, and 4 (P õ .05).
therapy. These data suggest that IVIG may have inhibited T 
